Related Experiment Videos
Therapy of secondary T-cell immunodeficiencies with biological substances and drugs
1Division of Immunopharmacology, University of South Florida College of Medicine, Tampa 33612.
Abstract:
Thymus-dependent (T) lymphocyte defects are common in cancer. Recent advances in the understanding of the regulation of T-cell development by biologicals and drugs now allow the formulation of better strategies of immune reconstitution to correct these defects. Thymic hormone preparations of several types offer one type of approach; however, they are somewhat limited in their reconstitutive ability. Interleukins (IL), particularly IL-1 and IL-2, appear to be complementary to the actions of thymic hormones in promoting T-cell development. Two classes of thymomimetic drugs have been identified and are represented by levamisole and isoprinosine. These drugs mimic by indirect and direct actions, respectively, the actions of thymic hormones. Newer analogs of these compounds have emerged which appear more effective. Also new factors, e.g. pituitary factors, are emerging which may be potent regulators of the immune system and useful in therapy. These agents may now be more effectively integrated with cytodestructive therapy in cancer treatment.
Insights
Strategies to correct T-cell defects in cancer patients are improving. Thymic hormones, interleukins (IL), and thymomimetic drugs like levamisole offer new immune reconstitution approaches. These can be integrated with cancer therapy.
Area of Science:
- Immunology
- Oncology
- Pharmacology
Background:
- Thymus-dependent (T) lymphocyte defects are prevalent in cancer patients.
- Understanding T-cell development regulation is key for immune reconstitution strategies.
- Existing therapies like thymic hormones have limitations in restoring T-cell function.
Purpose of the Study:
- To review recent advances in T-cell development regulation.
- To explore novel strategies for immune reconstitution in cancer.
- To discuss the integration of immunomodulatory agents with cancer treatment.
Main Methods:
- Review of current literature on T-cell development and immune reconstitution.
- Analysis of thymic hormone preparations, interleukins (IL-1, IL-2), and thymomimetic drugs (levamisole, isoprinosine).
- Discussion of emerging factors like pituitary factors and their therapeutic potential.
Main Results:
- Thymic hormones, while useful, have limited reconstitutive capacity.
- Interleukins (IL-1, IL-2) complement thymic hormones in T-cell development.
- Thymomimetic drugs (levamisole, isoprinosine) and their analogs offer direct and indirect T-cell modulation.
- New factors, including pituitary factors, show promise for immune regulation and therapy.
Conclusions:
- Advances in understanding T-cell regulation enable improved immune reconstitution strategies.
- A combination of thymic hormones, interleukins, and thymomimetic drugs can enhance T-cell function.
- Emerging immunomodulatory agents and factors can be effectively integrated with cytodestructive cancer therapy.